CRISPR-Based Programmable Nucleic Acid-Binding Protein Technology Can Specifically Detect Fatal Tropical Disease-Causing Pathogens

Md. Rashidur Rahman 1, Toma Rani Majumder 2, Md. Aminul Islam Apu 3, Alok K. Paul 4, Afrina Afrose 5, and Biplab Kumar Dash 2

1Department of Pharmacy, Jashore University of Science and Technology, Jashore 7408, Bangladesh
2Department of Genetic Engineering and Biotechnology, Jashore University of Science and Technology, Jashore 7408, Bangladesh
3Department of Biotechnology and Genetic Engineering, Islamic University, Kushtia 7003, Bangladesh
4Department of Biotechnology and Genetic Engineering, University of Development Alternative, Dhaka 1207, Bangladesh
5Department of Pharmacy, BRAC University, Dhaka 1212, Bangladesh

Correspondence should be addressed to Afrina Afrose; afrina.afrose@bracu.ac.bd and Biplab Kumar Dash; bk.dash.gebt@just.edu.bd

Received 18 March 2022; Revised 13 June 2022; Accepted 28 June 2022; Published 18 July 2022

1.Introduction

A rapid and precise diagnosis is vital for effectively controlling an infectious disease outbreak. Nucleic acid-based pathogen detection has frequently been used in clinical laboratories because of its specificity, sensitivity, and robustness. PCR, which can detect target nucleic acid from a trace amount of clinical samples, has been adopted as the gold standard for nucleic acid-based diagnostics. However, PCR amplification exclusively requires an expensive laboratory setup, expert personnel, careful separate pre-assay preparation time, and post-assay analysis. Advanced
isothermal nucleic acid amplification technologies, including helicase-dependent amplification [1], recombinase polymerase amplification (RPA) [2], loop-mediated isothermal amplification (LAMP) [3], rolling circle amplification, and nucleic acid sequence-based amplification (NASBA) [4], overcome the requirement of thermal cyclers, and require less assay time and cost than the conventional PCR. However, these methods are incompatible, especially for RLSs, because of shortcomings like minimal in-field sensitivity, nonspecific amplification, and inability to detect SNP [5, 6]. CRISPR-Cas systems as the next-generation technologies addressing the shortcomings mentioned above while facilitating POC diagnostic have gained immense interest.

The CRISPR-Cas strategy works as the only adaptive defense mechanism in bacteria and archaea to withstand reoccurring bacteriophage/phage invasion. In general, CRISPR-Cas systems deploy CRISPR RNA (crRNA) or a single-guide RNA (sgRNA)-led Cas endonuclease that sequence-specifically hybridize with the target sites of invader genomes, leading to spotting and cleaving intruder DNA or RNA [7]. Indeed, the flexibility of the CRISPR-Cas system to reprogram its crRNAs for recognizing and editing any nucleic acid sequence has made this tool exquisitely powerful to use in various cells and organisms with immense diagnostic and therapeutic potential [8–10].

Based on the evolutionary relationships, CRISPR-Cas systems can be grouped into two classes (class I comprises multiple effector proteins while class II has a single crRNA-binding protein), six types, and over 30 sub-types [11]. Several in-depth reviews have covered the characteristics of different CRISPR-Cas systems [6, 12, 13]. In the case of type II CRISPR-Cas9 system (Cas9 from Streptococcus pyogenes, S. thermophilus, Staphylococcus aureus, Neisseria meningitidis, and Campylobacter jejuni), an RNA duplex formed by a trans-activating crRNA (tracrRNA) bound crRNA fuses with the hairpin-rich region of a 20-nucleotide-long sgRNA that is complementary to a protospacer region of the target double-stranded DNA (dsDNA) sequence [7]. Successful recognition and binding of the target sequence by sgRNA brings Cas9 into close proximity to the target and unleashes its nuclease activity, resulting in DNA strand cleavage, forming a blunt-ended double-strand break (DSB) at the target site [7, 14]. Two distinct domains of the Cas9 accomplish this target-specific cleavage; the His-Asn-His (HNH)-like nuclease domain breaks the DNA strand complementary to the target strand while the RuvC-like nuclease domain cleaves another (non-target) strand of the dsDNA duplex [15]. The DSB is then repaired by the most frequent and efficient error-prone nonhomologous end joining or by the high-fidelity homology-directed repair pathway resulting in particular genome editing at the DSB site using a homologous repair template [7, 14]. Indeed, Cas9 can be engineered to recognize virtually any single-stranded DNA (ssDNA) or RNA (ssRNA) sequence by introducing a protospacer adjacent motif (PAM)-presenting oligonucleotides sequence located 3-4 nucleotides downstream of the protospacer [16].

The recently reported Cas9-based leveraging engineered tracrRNAs and on-target DNAs for parallel RNA detection (LEOPARD) method can simultaneously detect RNAs with single-nucleotide specificity from different viruses in a single run in patient samples [17].

Recent discoveries of several other CRISPR-Cas systems, including type V (Cas12 from Francisella novicida, Acidaminococcus sp., Lachnospiraceae sp., and Prevotella sp.) and type VI (Cas13 from Leptotrichia buccalis, L. shahii, Ruminococcus flavefaciens, Bergeyella zoohelcum, Prevotella buccae, and Listeria seeligeri), outstand CRISPR-based systems’ effectiveness towards prompt and accurate detection and genome editing of target organisms. Cas12 has two sub-types: Cas12a and Cas12f. Unlike the Cas9 system, Cas12 lacks HNH domain and thereby depends entirely on its RuvC domain to attain PAM-dependent cleavage of target dsDNA [14, 18, 19]. In addition, Cas12 can PAM-independently recognize and collaterally trigger ssDNA cleavage (referred to as trans-cleavage activity) [14]. Cas12f has a comparatively low size range of 400–700 amino acids (aa) than Cas9 (around 1400 aa) and Cas12a (around 1300 aa) and can target both dsDNA and ssDNA with better discrimination of single nucleotide differences in ssDNA than Cas12a [20]. The Cas13 enzyme family (like Cas13a and Cas13b), with a size range of 900–1300 aa, recognizes target ssRNA and exhibits trans-cleavage activity against ssRNA. Cas13a and Cas13b proteins target the protospacer flanking site, a specific nucleotide next to the 3’ end of the protospacer, for their activities [21, 22]. Figure 1 represents a simplified diagram describing two CRISPR-based nucleic acid detection assays (SHERLOCK and DETECTR) employing the Cas trans-cleavage activity.

Next-generation CRISPR-based molecular diagnostics use combined nucleic acid amplification steps with CRISPR-Cas system (Table 1). Specific high-sensitivity enzymatic reporter unlocking (SHERLOCK), one-hour low-cost multipurpose highly efficient system (HOLMES and HOLMESv2), and DNA endonuclease-targeted CRISPR trans-reporter (DETECTR), for example, have been reported in the ultrasensitive detection of DNA and RNA viruses, bacteria, protozoa, and SNP [24, 26, 27, 31–33]. In addition, SHERLOCKv2 facilitates single-reaction quantitative multiplexing with orthogonal CRISPR enzymes (i.e., multiple Cas13 and Cas12 enzymes) that simultaneously detect different targets at zeptomolar (10−21 M) concentrations on a portable paper-based lateral flow readout [34]. Another study by Ackerman and colleagues demonstrated combinatorial arrayed reactions for multiplexed evaluation of nucleic acids (CARMEN), a CRISPR-Cas13-based nucleic acid detection platform that can robustly detect 4500 crRNA-target pairs on a single microwell array [30]. Furthermore, combining HUDSON (heating unextracted diagnostic samples to oblate nucleases) with SHERLOCK has provided a more straightforward detection of pathogens from body fluids like saliva, serum, and whole blood [9]. HUDSON does not require extra nucleic acid extraction steps; it facilitates heat- and chemical-reduction-based lysis of viral particles and inactivation of local nucleases in a sample for better target nucleic acid-endonuclease binding.
availability. Accomplishing these advanced and ultrasensitive attributes has made CRISPR-based pathogen detection even more appealing in response to rapid diagnosis and surveillance applications worldwide.

Tropical diseases like malaria, TB, and HIV-AIDS are widespread in rapidly expanding areas worldwide. However, a unique group of tropical diseases, including zika, chikungunya, and rabies, are most prevalent in low-income and impoverished populations [35]. Table 2 summarizes the advantages and disadvantages of non-CRISPR-based methods used in diagnosing tropical diseases discussed later in this article. RLSs, like regions where tropical and neglected tropical diseases are common, demand cheap, portable, sensitive, and rapid detection methods for diagnosing the disease-causing pathogens. With the considerably rapid advancement of CRISPR-based detection technologies, they can be employed to detect diseases as mentioned above, meeting the unmet criteria set by the global health respondents like World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) [36]. This review focuses on the usefulness of the CRISPR-Cas-based platform as an ideal diagnostic and surveillance technology for extensively monitoring tropical diseases, including malaria, zika, chikungunya, HIV-AIDS, TB, and rabies.

2. Use of CRISPR-Based Systems in Diagnosing Tropical Diseases

2.1. Malaria. Malaria is one of the acute and sometimes lethal vector-borne tropical diseases threatening nearly half of the population of 91 countries worldwide. Female Anopheles mosquitoes infected with protozoan parasites from the genus *Plasmodium* transmit this disease to humans. According to the WHO report, in 2020, the projected worldwide malaria cases were 241 million with 627000 deaths, around 14 million more cases with 69000 more deaths than in 2019. According to WHO, the African region contributed to more than 95% malaria cases and 96% malaria deaths alone, of which 80% were children under five years [37]. Among the six known species of the genus *Plasmodium* that can infect humans, *P. falciparum* and *P. vivax* are the most prevalent, accounting for 99.7% and 75% of infections in Sub-Saharan Africa and the Americas, respectively. Although commonly dispersed in malaria-endemic regions, *P. malariae*, *P. ovale curtisi*, and *P. ovale wallikeri* are often understudied. Nonetheless, they can produce uncomplicated vivax malaria-like illness and sometimes may even become fatal if not appropriately treated [38, 39]. *P. knowlesi*, a Southeast Asian long-tailed macaque parasite, zoonotically infects humans, causing more symptomatic malaria with higher parasite counts but similar morbidity to *P. malariae* infections [40].
## Table 1: Comparison of CRISPR-based diagnostics with nucleic acid preamplification steps used in detecting tropical diseases.

| Method      | Enzyme | Amplification | Applications                                                                 | Assay time (min) | Readout     | Target   | PAM specificity (based on CRISPR types) | Sensitivity | Cleavage pattern (based on CRISPR types) | References |
|-------------|--------|---------------|------------------------------------------------------------------------------|------------------|-------------|----------|-----------------------------------------|-------------|------------------------------------------|------------|
| NASBACC     | Cas9   | NASBA         | Discrimination between African and American Zika strains                     | 120–360          | Colorimetry | RNA      | 3′-NGG (SpCas9), 3′-NNGRRT (SaCas9), 3′-NNNNGATT (NmCas9) | fM          | Blunt                                    | [23]       |
| HOLMES      | Cas12a | PCR           | Discrimination of SNP and virus strains                                      | 105              | Fluorescence| DNA, RNA | 5′-TTTN or 5′-TTN, or 5′-YTN           | aM          | Staggered                                | [24, 25]   |
| HOLMESv2    | Cas12  | LAMP          | Discrimination of SNP, detection of RNA viruses and DNA methylation          | 75–120           | Fluorescence| DNA, RNA |                                            | aM          |                                          | [26]       |
| DETECTR     | Cas12a | RPA           | Detection of HPV16 and HPV18                                                  | 60–120           | Fluorescence| DNA      |                                            | aM          |                                          | [14]       |
| SHERLOCK    | Cas13  | NASBA or RPA  | Detection of ZIKV and DENV, and several bacteria and discrimination of SNP and virus strains | 180–300          | Fluorescence| DNA, RNA | 3′-H (LshCas13a), 5′-D, and 3′-NAN or 3′-NNA (BzCas13b) | aM          | Near U or A                              | [27]       |
| SHERLOCKv2  | Cas12, Cas13 | RPA     | Detection of ZIKV and DENV, and several bacteria and discrimination of SNP and virus strains | 60–180           | Fluorescence or lateral flow | DNA, RNA |                                            | zM          |                                          | [28, 29]   |
| CARMEN      | Cas13  | PCR or RPA    | Detection of 169 viruses, including SARS-CoV-2, HIV, Influenza, and Zika     | 200              | Fluorescence| DNA      |                                            | aM          |                                          | [30]       |

**Notes:** NASBA - nucleic acid sequence-based amplification; RPA - recombinase polymerase amplification; LAMP - loop-mediated isothermal amplification; HPV 16 and 18 - human papillomavirus sub-types 16 and 18; SARS-CoV-2 - severe acute respiratory syndrome coronavirus 2; fM - femtomolar (10^{-15}); aM - attomolar (10^{-18}); zM - zeptomolar (10^{-21}).
Table 2: Advantages and disadvantages of non-CRISPR-based detection techniques used in diagnosing tropical diseases.

| Tropical diseases | Diagnostics | Advantages | Disadvantages |
|-------------------|-------------|------------|---------------|
| Malaria           | Light microscopy, Rapid diagnostic tests | The gold standard for Malaria diagnosis, Widespread use in Africa | High operator dependency and low sensitivity, Chances of false-positive and false-negative results |
| Zika              | Antibody-based serological tests, NASBA, Serological test | Readily available, RNA sensitivity, Availability, Real-time detection, Portable, POC testing | False-positive results because of cross-reactivity with other flavivirus antigens, Inability to detect SNP, Poor sensitivity, cross-reactions, and false-positive results, Variable sensitivity, Inaccurate test results because of the window period |
| Chikungunya       | Rt-PCR, RT-LAMP, Western blot, ELISA, and radioimmunoprecipitation assay, NAAT | | |
| HIV-AIDS          | Microscopy and traditional tests | Low cost and availability, Early diagnosis | Capable of detecting only HIV-1, Low specificity, inability to discriminate latent or progressive TB |
| Tuberculosis      | Rapid immunohistochemistry and direct fluorescent antibody tests, RT-PCR | Valid for detecting mild to severe clinical symptoms | Inability to detect early stages of infection |

Like the most deadly diseases, early and species-specific accurate malaria diagnosis effective in RLSs is critical in controlling its spread and preventing further succession and transmission. A person infected with malaria parasites commonly suffers from high fevers, shaking chills, and flu-like illnesses that usually emerge 10–15 days after being bitten by infected mosquitoes. These symptoms are mostly indistinguishable from other viral hemorrhagic fevers, complicating the primary diagnosis [41, 42]. The current malaria diagnostic methods primarily focus on detecting P. falciparum infections and their by-products. Other non-falciparum species are often neglected for their detection or remain indiscriminate due to their “less-severe” type infection pattern, thereby frequently underrated for their prevalence and severity [42].

Although light microscopic analysis of stained blood films is treated as the gold standard for malaria diagnosis, shortcomings like high operator dependency and low sensitivity (the typical limit of detection is 100 parasites/μL), among others, restrict its use occasionally throughout much of Africa nowadays. Conventional Plasmodium-specific highly expressed histidine-rich protein 2 (HRP2) antigen-based rapid diagnostic tests (RDTs) were used to diagnose 74% of all malaria in Africa in 2015 [37]. Unfortunately, RDTs are ineffective in detecting P. knowlesi and asymptomatic malaria with a low number of parasites (under approximately 200 parasites/μL), may produce false-positive results even after resolution of infection, and false-negative results for very high falciparum parasitaemias and parasites with mutated/deleted hrp2 and hrp3 genes [10, 43].

In October 2020, a group of scientists led by James Collins reported a breakthrough field-level optimized malaria assay capable of species-specifically detecting the four most pathogenic Plasmodium species: P. falciparum, P. vivax, P. ovale, and P. malariae (even P. falciparum with mutated/deleted hrp2 and hrp3 genes). This assay utilizes the combined action of an isothermal reverse-transcriptase RPA (RT-RPA) and SHERLOCK to accurately detect symptomatic and asymptomatic malaria carriers by analyzing whole blood, plasma, serum, and dried blood samples [44]. An engineered CRISPR-Cas12a (also known as Cpf1) enzyme is programmed to become active when gRNAs bind explicitly with the target Plasmodium dsDNA sequences. A parallel integration of an RT-RAA step that transcripts target RNA into DNA further strengthens the test sensitivity and accuracy by multiplying target dsDNA motifs present in samples. Once activated, CRISPR-Cas12a indiscriminately cleaves nontarget ssDNA with a high turn-over rate of around 1250 collateral cleavage reactions per second. Generation of fluorophore signals due to this nontarget fluorophore-quencher labeled reporter ssDNA degradation helps denote the existence of Plasmodium-specific dsDNA in samples is displayed by a plate reader or a handheld fluorimeter. This assay is simple (a fully lyophilized one-pot SHERLOCK protocol that does not require any nucleic acid extraction steps), ultrasensitive (can detect less than two parasites/μL of blood, surpassing the WHO limit of detection in RLSs), and field-applicable (comprised of an optimized 10 min sample preparation step followed by a 60 min parasite detection reaction). In clinical samples, this assay accomplished 100% analytical sensitivity and specificity.

Another recent study by Cunningham and colleagues demonstrates novel proof-of-concept SHERLOCK assays that can robustly detect all human malaria-causing Plasmodium species, except P. knowlesi, and species-specifically discriminate P. vivax and P. falciparum [45]. They developed three independent SHERLOCK assays for detecting different Plasmodium species, such as the pan-Plasmodium SHERLOCK assay (which can detect all five Plasmodium species), P. falciparum SHERLOCK assay (which can detect P. falciparum only), and P. vivax SHERLOCK assay (basically can detect P. vivax but shows a low-level cross-reactivity for P. knowlesi). Unlike Lee et al., this assay programmed LwCas13a to selectively bind to the conserved 18s rRNA genes of human-infecting Plasmodium genomes, followed by genus-specific amplification at 37°C for 180 min.
with fluorescence measurements. Moreover, they reported developing a novel single nucleotide variation detection SHERLOCK assay prototype representing 73% sensitivity and 100% specificity in detecting *P. falciparum* dihydropterotate synthetase single nucleotide variant A581G. Although the prototype showed false-negative results at lower parasite densities, it outperformed amplicon-based deep sequencing in screening sulfadoxine (a primary antimalarial drug)-resistant malaria in RLSs.

Comparing these two published CRISPR-based malaria detection approaches, the assay described by Lee et al. outperforms that reported by Cunningham and colleagues. The former represents superior analytical sensitivity and specificity, a single-pot lyophilized reaction setup, a simple handheld fluorometer or lateral flow readout, requires reduced reaction time, and is cheaper and better suited for field use [44, 45]. Nonetheless, the latter defines excellent clinical trial performance to well-characterized diverse clinical samples and infected mosquitoes for *P. falciparum*. Both diagnostic modalities suggest future upgradation and clinical validation of these potential SHERLOCK-based assays for future use in POC malaria diagnosis, drug-resistance genotyping, and policy decision-making for efficient malaria management in RLSs.

2.2. Zika. ZIKV, a Flaviviridae family member, is transmitted to humans mainly by infected *Aedes aegypti* and *A. albopictus* mosquitoes biting. Human ZIKV infection was first documented in 1953 in Nigeria, and several mild human ZIKV-associated illnesses were reported in broad but confined geographical areas of Asia and Africa until the early 2000s [46, 47]. Starting with the Yap outbreak in the Federated States of Micronesia in 2007, mild and severe ZIKV infection has been reported outside of Asia and Africa, including French Polynesia (in 2013 and 2014), South Pacific islands (in 2014–2016), and Australia, Japan, and Norway (in 2014) [48]. In 2015–2016, the Americas observed an unprecedented acute autochthonous zika outbreak that expanded into 48 countries and American territories with more than 17.15 million confirmed cases. Until now, ZIKV outbreaks, including microcephaly and pregnancy losses, have been reported in more than 100 countries worldwide, including Africa, Asia, Europe, and the Indian and Pacific Oceans [65].

The standard ZIKV diagnostic tests include serological approaches like IgM-capture ELISA (CDC-MAC-ELISA), Liaison XL Zika Capture IgM test, and InBios Zika Detect IgM Capture ELISA. Nonetheless, high-sensitivity/low-specificity antibody tests are substandard as the zika IgM often cross-reacts with other flavivirus antigens (like West Nile, dengue, and yellow fever) if present in previously infected patient’s samples [57, 58]. An additional plaque reduction neutralization test can be used to verify MAC-ELISA results, but several serious shortcomings make its use impractical in RLSs [59]. Although viral particles and RNA have been spotted in breast milk, nasopharynx, serum, urine, vaginal fluids, and saliva of infected individuals, whether target ZIKV antibodies for ultrasensitive detection present in or ZIKV can be transmitted via these secretions are still undiscovered [60–62]. These phenomena and several common inborne drawbacks limit extensive use of traditional nucleic acid-based approaches like RT-PCR, RealTime ZIKA assay developed by Abbott laboratories [63], and Trioplex and primer and probe in-house test developed by CDC [64] in ZIKV detection.

A study by Collins et al. demonstrated a next-generation robust sequence-specific ZIKV detection scheme that attained clinically relevant sensitivity without any significant affinity for the shared dengue virus (DENV) genome [23]. This portable platform deploys in vitro freeze-dried cell-free expression systems combined with an extremely target RNA sensitive NASBA technology and programmable molecular sensors (i.e., RNA toehold switches) to detect the target sequence even in the low femtomolar range (10^{-15} M) from serum samples. Further adaption of Cas9 endonuclease (called as NASBA-CRISPR cleavage) technology provides selective strand break in the synthesized dsDNA only in the presence of a strain-specific NGG PAM that outperforms the former by enabling SNP detection. This advanced synthetic biological approach can differentiate distinct African and American zika strains and closely related ZIKV and DENV [23, 27, 34]. Further validation using laboratory cultured zika strains (spiked into 7% water diluted human serum) and infected viremic macaque plasma (1:10 water dilution) exhibited potential POC diagnostic use in RLSs at 3–5 hours running time at the cost of 2–16 USD per transcript. Another study by Myhrvold and colleagues demonstrated a protocol pairing Cas13-based SHERLOCK with HUDSON that can detect region-specific zika strains and DENV directly from patients’ body fluids at concentrations as low as one copy per microliter in less than two hours with minimal equipment [9].

2.3. Chikungunya. Chikungunya is a neglected tropical disease primarily transmitted by Chikungunya virus (CHIKV)-infected *A. aegypti* and *A. albopictus* mosquitoes (same mosquitoes transmitting DENV) to humans [65]. In the last 20 years, several CHIKV outbreaks have been reported in more than 100 countries worldwide, including Africa, Asia, Europe, and the Indian and Pacific Oceans (https://www.cdc.gov/chikungunya/geo/index.html). Furthermore, co-infection of CHIKV with DENV [66] and
CHIKV with ZIKV, DENV, yellow fever virus, or West Nile virus have been reported [67, 68]. Considering its alarming and unprecedented increase in spread in the last decade, WHO listed CHIKV as one of the blueprint priority pathogens (https://www.who.int/blueprint/en/).

Although first spotted in 1952 from the serum of a febrile patient in Tanzania [69], CHIKV’s physiology, pathogenesis, transmission, or diagnosis methods are still ambiguous [70]. CHIKV-infected persons experience clinical symptoms substantially similar to those caused by DENV, ZIKV, and malaria parasite, including fever (ranges from mild fever to encephalitis and hemorrhagic fevers), polyarthralgia, myalgia, widespread skin rash, and conjunctivitis [68, 71]. Chikungunya infection at an early age (immediately after the birth) or older age (>65 years) and especially with comorbidities like diabetes and cardiovascular disorders can sometimes be deadly [72].

Lab culturing patient samples may confirm CHIKV infection in the first three days of illness; the requirement of a biosafety level III conditions limits its use in LRSs [73]. Several serological detection approaches, including CHIKV-specific IgM antibody test (in serum samples after 5–7 days of symptom onset) and IgG and IgM capture ELISA (in serum/plasma samples better after 3–5 weeks of symptom onset), are available. However, poor-sensitivity, cross-reactivity, and false-positive tests due to co-infection with the Semliki Forest antigenic complex group, such as Mayaro and O’nyong-nyong (and other closely related alphaviruses), have been reported [74]. Moreover, samples collected during the first week of illness require an additional CHIKV RNA (in serum or plasma/EDTA sample) detection RT-PCR test for further confirmation. Real-time RT-PCR [75], quantitative RT-LAMP [76], and a single assay for combined detection of ZIKV, DENV, and CHIKV [77, 78] have been reported, but they are of variable sensitivity. Only a molecular reference ZIKV, DENV, and CHIKV [77, 78] have been reported, but they are of variable sensitivity. Only a molecular reference sequence of these viruses has been used for the detection of these viruses in clinical samples.

The gene-editing attribute of CRISPR-Cas9 has recently been employed to perform genome-wide screenings to identify and validate two structurally homologous compounds: CD147 [79] and Mxr8 [80], essential for CHIKV entry into host cells. In addition, another report demonstrated the capability of Cas13b nuclease to identify and degrade CHIKV RNA even in mosquito vectors [81]. However, by far the best of our knowledge, any CRISPR-based CHIKV detection method has been reported.

2.4. HIV-AIDS. AIDS is a chronic infectious disease caused by the most advanced stage of HIV infection in humans where the infected person gradually becomes immunodeficient as the HIV impairs regular functions of immune cells. AIDS is characterized by increased risks of infectious and oncological difficulties contributing to common comorbidities, including cardiovascular, renal, and hepatic dys-function. Since being discovered in the 1980s, this virus has created a global pandemic claiming more than 36 million lives, where most of the deceased were from a confined Sub-Saharan Africa region (https://www.who.int/news-room/fact-sheets/detail/hiv-aids). Depending on the clinical symptom presentations, it usually takes several years for AIDS patients to experience serious complications; thereby, diagnostics capable of detecting early phase infections can maximize life expectancy [82].

Depending on the progression of HIV viremia after initial infection, tests including Western blot, ELISA, and radio-immunoprecipitation can precisely diagnose HIV antibodies in a patient’s serum or plasma 3–7 weeks after infection [83]. Moreover, an HIV RNA amplification test, NAAT, can screen for HIV-1 infection (but not HIV-2) as early as after one week of illness. However, fourth-generation tests like confirmation and detection of p24 antigen and combined HIV IgG and IgM antibodies have been recommended by the US CDC and European guidelines for HIV testing as standard for acute HIV-1 and HIV-2 diagnosis within 2–3 weeks of infection. These organizations also recommend using HIV-2-specific nucleic acid-based differential tests in samples that tested negative or intermediate HIV-1 infection by standard tests [84, 85]. Several advanced methods, including HIV-2 RT-PCR Kit [86], 5′-long terminal repeats-targeting HIV-2 PCR assay [87], and the latest automated Cobas HIV-1/2 Qual test [88] have been proposed for efficient HIV-1/2 differentiation and confirmation; however, FDA-approved nucleic acid-based differential methods are still in development [89].

A preprint posted in bioRXiv introduced an all-in-one dual CRISPR-Cas12a (AID-CRISPR) assay method to detect HIV-1 DNA and RNA with a sensitivity as low as a few copies (https://doi.org/10.1101/2020.03.19.998724). This truly isothermal and robust one-pot reaction assay can detect 1.2 copies of HIV-1 p24 plasmids in just 40 min of incubation. Prospective CRISPR-based next-generation HIV-1/2 diagnostics are likely about to report overtaking the existing standard tests.

2.5. TB. TB is Mycobacterium tuberculosis (MtB)-borne bacterial infection transmitted through the air carrying tiny droplets from the coughs or sneezes of an infected person. Although MtB primarily causes pulmonary disease affecting the lungs, it can harm tissues like the kidney, spine, and brain (https://www.cdc.gov/tb/default.htm). Among a quarter of the world’s population infected with MtB, only 10% progress to active TB disease, where 40% of the total cases remain unnoticed and unrecognized. MtB can be contained in infected persons in a latency period without exhibiting any clinical TB symptoms even for many years [90]. Moreover, the risk of becoming a progressive TB patient multiplies if a person coinfected with immunocompromising conditions. For example, in Sub-Saharan Africa, about 75% of TB patients are coinfected with HIV-AIDS, making diagnosing and monitoring MtB infection challenging [91]. Nevertheless, WHO keeps inexpensive tools capable of screening and diagnosing MtB at the early stage of disease and in LRSs at the top of its proposed TB control strategies.
TB testing methods are currently accessible in a variety of forms. Microscopic examination of the presence of acid-fast bacilli in stained sputum smears and gastric aspirate, for instance, can primarily detect Mtb infection with 50–60% specificity (mainly used in low- and middle-income countries). Traditional tests like Mantoux tuberculin skin test, TB blood test, and interferon-γ release assays (IGRAs, in low *tuberculosis* prevalence settings) cannot distinguish between latent or progressive TB and demand additional confirmatory tests like chest radiography and computer-aided imaging. Among the rapid Mtb nucleic acid diagnostic tests, WHO recommends using Xpert MTB/RIF Ultra and TB LAMP. Together with other technologies endorsed by WHO, these tests proved effective in diagnosing HIV-associated and different resistant forms of TB [92–96]. However, their roll-out has barely improved the global TB detection rates since they are sophisticated and expensive with limited effectiveness [90].

A CRISPR-MTB test approach has been reported to detect Mtb in direct clinical samples, including sputum, bronchoalveolar lavage fluid, CSF, pleural fluid, ascites, and pus with improved sensitivity (i.e., with a near single-copy), less sample input, and quicker turnaround time than GeneXpert MTB/RIF and culture assays [97]. Another recent study developed a successful species-specific gRNA-driven Cas12a-based Mtb rpoB sequence detection platform capable of detecting human Mtb and six nontuberculous mycobacterial species (clinical isolates) in three hours without any false-positive results [98]. Lyu et al. emphasized the potential of using the CRISPR platform in low-cost, rapid, and highly responsive diagnosis of pediatric TB as well [99].

Zhang and colleagues introduced an engineered nuclease deficient Cas9 (dCas9)-based in vitro DNA detection system that can reliably detect the human Mtb genome while preserving the functional repertoire of nucleic acids [100]. They demonstrated a pair of dCas9 reporter proteins heterodimerized with the N- and C-terminal cleaved firefly luciferase enzymes guided by single-guide RNAs to complement ~44 bp upstream and downstream target sequences, respectively. The presence of the target DNA sequence leads the two segments to reside nearby, followed by the catalytic activity of luciferase to create and measure luminescence signals in a lateral readout. This technology is promising in clinical RLSs in multiplex detection of low concentration target genomes even when samples become contaminated with ample nonspecific DNA.

### 2.6. Rabies

Rabies is a neglected tropical disease caused by rabies virus (RABV), a negative-sense single-stranded neurotropic virus belongs to the *Lyssavirus* genus in the *Rhabdoviridae* family. As a zoonotic disease, rabies is endemic in most parts of the world, particularly in resource-limited countries in Africa and Asia, taking around 60,000 human lives annually [101, 102]. RABV is naturally transmitted via infected animals’ saliva (transmission by tissue plantation has also been reported [103]), and infected dog bites are accountable in more than 99% of reported human cases. Early clinical symptoms of rabies infection are primarily nonspecific, including fever with pain, tingling, and burning sensation in the bitten areas. Although clinically indistinguishable from GBS and cerebral malaria, RABV-specific symptoms only appear when the virus replicates in the central nervous system [104]. Once the virus infects the human brain, it causes acute encephalomyelitis with a nearly 100% mortality rate, as there is no effective treatment [103].

Commonly used tests to detect RABV infection include viral nucleocapsid antigens-specific rapid immunohistochemistry and direct fluorescent antibody tests (FAT), and viral RNA-specific RT-PCR (even RT-PCR-ELISA) [105–107]. FAT is generally valid for postmortem cases since viral antigens reach to detectable range only at the final phase of the disease. In the case of intra-vitam human rabies routine diagnosis, conventional and real-time quantitative RT-PCR targeting the highly conserved viral N or L gene has been employed widely. These detection methods have similar sensitivity and specificity for RABV and are valid for detecting mild to severe clinical symptoms bearing host samples [108]. Nonetheless, besides the typical drawbacks, these methods are invalid in the early stages of infection when the viral loads are low, and only a few of these methods have been validated for widescale use in clinical conditions [109, 110].

Recently, an RPA-CRISPR-Cas13a approach demonstrated viral RNA detection from a model rat’s cerebrospinal fluid (CSF) that paves the way for early-stage (i.e., three days post-infection) RABV detection [111]. This early rabies detection method has superior sensitivity, detecting as low as a single copy of RABV genomic RNA per microliter CSF. However, a few limitations, including yet to apply with human samples in clinical settings and the requirement of a rigorous primer screening before sample analysis, demand further improvement and validation of this method in using in RLSs.

### 3. Conclusion

The CRISPR-Cas-based detection tools have revolutionized modern medical facilities, especially with their increasingly inexpensive, precise, ultrasensitive, multiplexing, and robust pathogen detection strategies. These tools hold pronounced perspectives for POC applications and routine clinical care in remote LRSs, basically where novel and recurrent tropical outbreaks occur. Applications of cell-free synthetic biological approaches have made these tools even more attractive to use in a low-cost manner allowing for easy storage and distribution in global settings. Moreover, the freeze-drying paper-based platforms overcome mandatory laboratory settings without concern over biosafety. Nonetheless, most of the next-generation CRISPR tools have not yet been validated beyond proof-of-concept applications in real-world clinical conditions and have not been officially approved by the regulatory agencies for extensive field-level uses. Considering their potential, we believe overcoming these limitations is a mere matter of time, and further development of CRISPR-based diagnostics will contribute to challenging global health crises in convincing ways.
Conflicts of Interest

The authors report that there are no conflicts of interest to declare.

References

[1] Y. Li, N. Kumar, A. Gopalakrishnan et al., “Detection and species identification of malaria parasites by isothermal tHDA amplification directly from human blood without sample preparation,” *Journal of Molecular Diagnostics*, vol. 15, no. 5, pp. 634–641, 2013.

[2] S. Kersting, V. Rausch, F. F. Bier, and M. von Nickisch-Rosenegk, “Rapid detection of *Plasmodium falciparum* with isothermal recombinase polymerase amplification and lateral flow analysis,” *Malaria Journal*, vol. 13, no. 1, p. 99, 2014.

[3] B. A. Schmidt, W. Xu, I. J. González et al., “Loop mediated isothermal amplification (LAMP) accurately detects malaria DNA from filter paper blood samples of low density parasitaemia,” *PloS One*, vol. 9, no. 8, Article ID e103905, 2014.

[4] B. Deiman, P. van Aarle, and P. Sillekens, "Characteristics and applications of nucleic acid sequence-based amplification (NASBA)," *Molecular Biotechnology*, vol. 20, no. 2, pp. 163–180, 2002.

[5] H. Hopkins, I. J. González, S. D. Polley et al., “Highly sensitive detection of malaria parasitemia in a malaria-enemic setting: performance of a new loop-mediated isothermal amplification kit in a remote clinic in Uganda,” *The Journal of Infectious Diseases*, vol. 208, no. 4, pp. 645–652, 2013.

[6] M. M. Kaminski, O. O. Abudayyeh, J. S. Gootenberg, F. Zhang, and J. J. Collins, “CRISPR-based diagnostics,” *Nature Biomedical Engineering*, vol. 5, no. 7, pp. 643–656, 2021.

[7] M. Jinek, K. Chylinski, I. Fonfara, M. Hauer, J. A. Doudna, and E. Charpentier, “A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity,” *Science*, vol. 337, no. 6096, pp. 816–821, 2012.

[8] F. Hille and E. Charpentier, “CRISPR-Cas: biology, mechanisms and relevance,” *Philosophical Transactions of the Royal Society B: Biological Sciences*, vol. 371, no. 1707, Article ID 20150496, 2016.

[9] C. Myhrvold, C. A. Freije, J. S. Gootenberg et al., “Field-deployable viral diagnostics using CRISPR-Cas13,” *Science Series*, vol. 360, no. 6387, pp. 444–448, 2018.

[10] H. Wang, M. La Russa, and L. S. Qi, “CRISPR/Cas9 in genome editing and beyond,” *Annual Review of Biochemistry*, vol. 85, no. 1, pp. 227–264, 2016.

[11] K. S. Makarova, Y. I. Wolf, O. S. Alkhnbashi et al., “An updated evolutionary classification of CRISPR-Cas systems,” *Nature Reviews Microbiology*, vol. 13, no. 11, pp. 722–736, 2015.

[12] W. Feng, A. M. Newbigging, J. Tao et al., “CRISPR technology incorporating amplification strategies: molecular assays for nucleic acids, proteins, and small molecules,” *Chemical Science*, vol. 12, no. 13, pp. 4683–4698, 2021.

[13] X. Liu, M. Hussain, J. Dai et al., “Programmable biosensors based on RNA-guided CRISPR/Cas endonuclease,” *Biological Procedures Online*, vol. 24, no. 1, p. 2, 2022.

[14] J. S. Chen, E. Ma, L. B. Harrington et al., “CRISPR-Cas12a target binding unleashed indiscriminate single-stranded DNase activity,” *Science Series*, vol. 360, no. 6387, pp. 436–439, 2018.

[15] H. Nishimasu, F. A. Ran, P. D. Hsu et al., “Crystal structure of Cas9 in complex with guide RNA and target DNA,” *Cell*, vol. 156, no. 5, pp. 935–949, 2014.

[16] M. R. O’Connell, B. L. Oakes, S. H. Sternberg, A. East-Seletsky, M. Kaplan, and J. A. Doudna, “Programmable RNA recognition and cleavage by CRISPR/Cas9,” *Nature*, vol. 516, no. 7530, pp. 263–266, 2014.

[17] C. Jiao, S. Sharma, G. Dugar et al., “Noncanonical crRNAs derived from host transcript enables multiplexable RNA detection by Cas9,” *Science Series*, vol. 372, no. 6545, pp. 941–948, 2021.

[18] S. Shmakov, O. O. Abudayyeh, K. S. Makarova et al., “Discovery and functional characterization of diverse class 2 CRISPR-cas systems,” *Molecular Cell*, vol. 60, no. 3, pp. 385–397, 2015.

[19] B. Zetsche, J. S. Gootenberg, O. O. Abudayyeh et al., “Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system,” *Cell*, vol. 163, no. 3, pp. 759–771, 2015.

[20] L. B. Harrington, D. Burststein, J. S. Chen et al., “Programmed DNA destruction by miniature CRISPR-Cas14 enzymes,” *Science Series*, vol. 362, pp. 6416, pp. 839–842, 2018.

[21] O. O. Abudayyeh, J. S. Gootenberg, S. Konermann et al., “C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector,” *Science*, vol. 353, no. 6299, pp. 353, 2016.

[22] A. East-Seletsky, M. R. O’Connell, S. C. Knight et al., “Two distinct RNase activities of CRISPR-C2c2 enable guide-RNA processing and RNA detection,” *Nature*, vol. 538, no. 7624, pp. 270–273, 2016.

[23] K. Pardee, A. A. Green, M. K. Takahashi et al., “Rapid, low-cost detection of zika virus using programmable biomolecular components,” *Cell*, vol. 165, no. 5, pp. 1255–1266, 2016.

[24] S.-Y. Li, Q.-X. Cheng, J.-M. Wang et al., “CRISPR-Cas12a-assisted nucleic acid detection,” *Cell Discovery*, vol. 4, no. 1, p. 20, 2018.

[25] S.-Y. Li, Q. X. Cheng, J. K. Liu, X. Q. Nie, G. P. Zhao, and J. Wang, “CRISPR-Cas12a has both cis- and trans-cleavage activities on single-stranded DNA,” *Cell Research*, vol. 28, no. 4, pp. 491–493, 2018.

[26] L. Li, S. Li, N. Wu et al., “HOLMESv2: a CRISPR-Cas12b-assisted platform for nucleic acid detection and DNA methylation quantitation,” *ACS Synthetic Biology*, vol. 8, no. 10, pp. 2228–2237, 2019.

[27] J. S. Gootenberg, O. O. Abudayyeh, J. W. Lee et al., “Nucleic acid detection with CRISPR-Cas13a/C2c2,” *Science Series*, vol. 356, no. 6336, pp. 438–442, 2017.

[28] J. S. Gootenberg, O. O. Abudayyeh, M. J. Kellner, J. Joung, J. J. Collins, and F. Zhang, “SHERLOCK: nucleic acid detection with CRISPR nucleases,” *Nature Protocols*, vol. 14, no. 10, pp. 2986–3012, 2019.

[29] C. M. Ackerman, C. Myhrvold, S. G. Thakku et al., “Massively multiplexed nucleic acid detection with Cas13,” *Nature*, vol. 582, no. 7811, pp. 277–282, 2020.

[30] J. P. Broughton, X. Deng, G. Yu et al., “CRISPR-Cas12b-based detection of SARS-CoV-2,” *Nature Biotechnology*, vol. 38, no. 7, pp. 870–874, 2020.
species-specific real-time PCR assays,” *Journal of Clinical Microbiology*, vol. 42, no. 12, pp. 5636–5643, 2004.

[33] L. Vachot-Ganée, N. Khim, A. Iannello et al., “A novel field-based molecular assay to detect validated artemisinin-resistant *k13* mutants,” *Malaria Journal*, vol. 17, no. 1, p. 175, 2018.

[34] H. de Puig, I. Bosch, J. J. Collins, and L. Gehrke, “Point-of-care devices to detect zika and other emerging viruses,” *Annual Review of Biomedical Engineering*, vol. 22, no. 1, pp. 371–386, 2020.

[35] P. J. Hotze, S. Aksoy, P. J. Brindley, and S. Kamhawi, “What constitutes a neglected tropical disease?” *PLoS Neglected Tropical Diseases*, vol. 14, no. 1, Article ID e0008001, 2020.

[36] H. Kettler, K. White, and S. Hawkes, *Mapping the Landscape of Diagnostics for Sexually Transmitted Infections: Key Findings and Recommendations*, World Health Organization, Geneva, Switzerland, 2004.

[37] World Health Organization, *World Malaria Report 2021*, World Health Organization, Geneva, Switzerland, 2021.

[38] E. A. Ashley, A. P. Phyo, and C. J. Woodrow, “Malaria,” *The Lancet*, vol. 391, no. 10130, pp. 1608–1621, 2018.

[39] I. Mueller, P. A. Zimmerman, and J. C. Reeder, “*Plasmodium malariae* and *Plasmodium ovale*—the "bush malaria" parasites,” *Trends in Parasitology*, vol. 23, no. 6, pp. 278–283, 2007.

[40] M. A. Ahmed and J. C. Singh, “*Plasmodium knowlesi*—an emerging pathogen,” *ISBT Science Series*, vol. 10, no. S1, pp. 134–140, 2015.

[41] C. L. B. Gadia, A. Manirakiza, G. Tekpa, X. Konamna, U. Vickos, and E. Nakoue, “Identification of pathogens for differential diagnosis of fever with jaundice in the central African republic: a retrospective assessment, 2008–2010,” *BMC Infectious Diseases*, vol. 17, no. 1, p. 735, 2017.

[42] A. M. Gimenez, R. F. Marques, M. Regiart, and D. Y. Bargieri, “Diagnostic methods for non-falciparum *Plasmodium* species in symptomatic and asymptomatic malaria,” *Frontiers in Cellular and Infection Microbiology*, vol. 11, Article ID 681063, 2021.

[43] C. F. Markwalter, L. E. Gibson, L. Mudenda et al., “Characterization of *Plasmodium* lactate dehydrogenase and histidine-rich protein 2 clearance patterns via rapid on-head detection from a single dried blood spot,” *The American Journal of Tropical Medicine and Hygiene*, vol. 98, no. 5, pp. 1389–1396, 2018.

[44] R. A. Lee, H. De Puig, P. Q. Nguyen et al., “Ultrasensitive CRISPR-based diagnostic for field-applicable detection of *Plasmodium* species in symptomatic and asymptomatic malaria,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 117, no. 41, Article ID 25731, 2020.

[45] C. H. Cunningham, C. M. Hennelly, J. T. Lin et al., “A novel CRISPR-based malaria diagnostic capable of *Plasmodium* detection, species differentiation, and drug-resistance genotyping,” *Elife*, vol. 68, Article ID 103415, 2021.

[46] F. N. MacNamara, “Zika virus: a report on three cases of human infection during an epidemic of jaundice in Nigeria,” *Transactions of the Royal Society of Tropical Medicine and Hygiene*, vol. 48, no. 2, pp. 139–145, 1954.

[47] B.-H. Song, S.-I. Yun, M. Woolley, and Y.-M. Lee, “Zika virus: history, epidemiology, transmission, and clinical presentation,” *Journal of Neuroimmunology*, vol. 308, pp. 50–64, 2017.

[48] L. R. Petersen, D. J. Jamieson, A. M. Powers, and M. A. Honein, “Zika virus,” *New England Journal of Medicine*, vol. 374, no. 16, pp. 1552–1563, 2016.

[49] CDC, *Potential Range of Aedes aegypti and Aedes albopictus in the United States*, 2017, CDC Stacks, Atlanta, GA, USA, 2017.

[50] P. Ferraris, H. Yssel, and D. Missé, “Zika virus infection: an update,” *Microbes and Infection*, vol. 21, no. 8–9, pp. 353–360, 2019.

[51] Pan America Health Organization, *Epidemiological Update: Dengue, Chikungunya and Zika in the Context of COVID-19*, Pan America Health Organization, Washington, DC, USA, 2021.

[52] CDC: https://www.cdc.gov/zika/index.html.

[53] Microcephaly Epidemic Research Group, *Microcephaly in infants, Pernambuco state, Brazil, 2015,* *Emerging Infectious Diseases*, vol. 22, no. 6, pp. 1090–1093, 2016.

[54] E. Oehler, L. Watrin, P. Larre et al., “Zika virus infection complicated by guillain-barre syndrome-case report, French Polynesia, December 2013,” *Euro Surveill*, vol. 19, no. 9, Article ID 20720, 2014.

[55] S. A. Rasmussen, D. J. Jamieson, M. A. Honein, and L. R. Petersen, “Zika virus and birth defects—reviewing the evidence for causality,” *New England Journal of Medicine*, vol. 374, no. 20, pp. 1981–1987, 2016.

[56] L. Schuler-Faccini, E. M. Ribeiro, I. M. L. Fetto et al., “Possible association between zika virus infection and microcephaly—Brazil, 2015,” *MMWR. Morbidity and Mortality Weekly Report*, vol. 65, no. 3, pp. 59–62, 2016.

[57] M. L. Landry and K. St George, “Laboratory diagnosis of zika virus infection,” *Archives of Pathology & Laboratory Medicine*, vol. 141, no. 1, pp. 60–67, 2017.

[58] J. L. Munoz-Jordan, “Diagnosis of zika virus infections: challenges and opportunities,” *The Journal of Infectious Diseases*, vol. 216, no. 10, pp. S951–S956, 2017.

[59] M. Kikuti, L. B. Tauro, P. S. S. Moreira et al., “Diagnostic performance of commercial IgM and IgG enzyme-linked immunoassays (ELISAs) for diagnosis of zika virus infection,” *Virology Journal*, vol. 15, no. 1, p. 108, 2018.

[60] M. C. Ronaldo, I. P. Ribeiro, N. S. Lima et al., “Isolation of infective zika virus from urine and saliva of patients in Brazil,” *PLoS Neglected Tropical Diseases*, vol. 10, no. 6, Article ID e0004816, 2016.

[61] R. S. Lanciotti, O. L. Kosoy, J. J. Laven et al., “Genetic and serologic properties of zika virus associated with an epidemic, Yap state, Micronesia, 2007,” *Emerging Infectious Diseases*, vol. 14, no. 8, pp. 1232–1239, 2008.

[62] P. Pielnaa, M. Al-Saadawe, A. Saro et al., “Zika virus-spread, epidemiology, genome, transmission cycle, clinical manifestation, associated challenges, vaccine and antiviral drug development,” *Virology*, vol. 543, pp. 34–42, 2020.

[63] M. B. Frankel, K. Pandya, J. Gersch, S. Siddiqui, and G. J. Schneider, “Development of the Abbott real-time zika assay for the qualitative detection of zika virus RNA from serum, plasma, urine, and whole blood specimens using the m2000 system,” *Journal of Virological Methods*, vol. 246, pp. 117–124, 2017.

[64] M. R. Duffy, T.-H. Chen, W. T. Hancock et al., “Zika virus outbreak on Yap island, Federated states of Micronesia,” *New England Journal of Medicine*, vol. 360, no. 24, pp. 2536–2543, 2009.

[65] P. J. Mason and A. J. Haddock, “An epidemic of virus disease in southern province, Tanganyika territory, in 1952–1953: an additional note on chikungunya virus isolations and serum antibodies,” *Transactions of the Royal Society of Tropical Medicine and Hygiene*, vol. 51, no. 3, pp. 238–240, 1957.
RNA expression,” *Communications Biology*, vol. 3, p. 413, 2020.

[82] M. S. Saag, “HIV infection—screening, diagnosis, and treatment,” *New England Journal of Medicine*, vol. 384, no. 22, pp. 2131–2143, 2021.

[83] S. Nandi, A. Mondal, A. Roberts, and S. Gandhi, “Biosensor platforms for rapid HIV detection,” in *Advances in Clinical Chemistry*, pp. 1–34, Elsevier, Amsterdam, Netherlands, 2020.

[84] B. M. Branson, S. M. Owen, L. G. Wesolowski et al., *Laboratory Testing for the Diagnosis of HIV Infection: Updated Recommendations*, CDC Stacks, Atlanta, GA, USA, 2014.

[85] D. Gökengin, A. M. Geretti, J. Begovac et al., “2014 European guideline on HIV testing,” *International Journal of STD & AIDS*, vol. 25, no. 10, pp. 695–704, 2014.

[86] M. Ciccozzi, M. Babakir-Mina, E. Cellà et al., “A case of Italian HIV type 2 infection: a genetic analysis,” *AIDS Research and Human Retroviruses*, vol. 27, no. 12, pp. 1333–1335, 2011.

[87] J. L. Greenwald, G. R. Burstein, J. Pincus, and B. Branson, “A rapid review of rapid HIV antibody tests,” *Current Infectious Disease Reports*, vol. 8, no. 2, pp. 125–131, 2006.

[88] L. Hans, N. von Allmen, A. Edelmann et al., “Early diagnosis of HIV-1 and HIV-2 using cobas HIV-1/HIV-2 qualitative test: a novel qualitative nucleic acid amplification test for plasma, serum, and dried blood spot specimens,” *JAIDS Journal of Acquired Immune Deficiency Syndromes*, vol. 87, no. 5, pp. 1187–1195, 2021.

[89] A. H. Peruski, L. G. Wesolowski, K. P. Delaney et al., “Trends in HIV-2 diagnoses and use of the HIV-1/HIV-2 differentiation test—United States, 2010–2017,” *MMWR. Morbidity and Mortality Weekly Report*, vol. 69, no. 3, pp. 63–66, 2020.

[90] G. Walzl, R. McNerney, N. du Plessis et al., “Tuberculosis: advances and challenges in development of new diagnostics and biomarkers,” *The Lancet Infectious Diseases*, vol. 18, no. 7, pp. e199–e210, 2018.

[91] K. K. Holmes, S. Bertozzi, B. R. Bloom, and P. Jha, “Tuberculosis,” in *Infectious Disease Control Priorities: Major Infectious Diseases*, pp. 233–313, The World Bank, Washington, DC, USA, 2017.

[92] S. Chakravorty, A. M. Simmons, M. Rowneki et al., “The new Xpert MTB/RIF ultra: improving detection of *Mycobacterium tuberculosis* and resistance to rifampin in an assay suitable for point-of-care testing,” *mBio*, vol. 8, no. 4, Article ID e00812-17, 2017.

[93] B. C. Dhar, N. Steinberg, and G. Mazzoleni, “Point-of-care pathogen detection with CRISPR-based programmable nucleic acid binding proteins,” *ChemMedChem*, vol. 16, no. 10, pp. 1566–1575, 2021.

[94] M. Pai and M. Behr, “Latent *Mycobacterium tuberculosis* infection and interferon-gamma release assays,” *Microbiology Spectrum*, vol. 4, no. 5, 2016.

[95] S. Pervere and R. Sharma, “Screening approaches and therapeutic targets: the two driving wheels of tuberculosis drug discovery,” *Biochemical Pharmacology*, vol. 197, Article ID 114906, 2022.

[96] J. G. Peter, L. S. Zijenah, D. Chanda et al., “Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-positive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomised controlled trial,” *The Lancet*, vol. 387, no. 10024, pp. 1187–1197, 2016.

[97] J.-W. Ai, X. Zhou, T. Xu et al., “CRISPR-based rapid and ultra-sensitive diagnostic test for *Mycobacterium tuberculosis* epigenetic and related alphaviruses in human cells,” *Journal of Clinical Virology*, vol. 39, no. 3, pp. 1003–1025, 2019.

[98] F. Vairo, N. Haider, R. Kock, F. Ntsoumi, G. Ippolito, and A. Zumla, “Chikungunya: epidemiology, pathogenesis, clinical features, management, and prevention,” *Infectious Disease Clinics of North America*, vol. 33, no. 4, pp. 1003–1025, 2019.

[99] S. C. Weaver and N. L. Forrester, “Chikungunya: evolutionary history and recent epidemic spread,” *Antiviral Research*, vol. 120, pp. 32–39, 2015.

[100] A. M. Powers, *Clinical in Laboratory Medicine*, Vol. 30, Elsevier, Amsterdam, Netherlands, 2010.

[101] B. Pastorino, M. Bessaud, M. Grandadam, S. Murri, H. J. Tolou, and C. N. Peyrefitte, “Development of a tagman® RT-PCR assay without RNA extraction step for the detection and quantification of African chikungunya viruses,” *Journal of Virological Methods*, vol. 124, no. 1-2, pp. 65–71, 2005.

[102] B. Pastorino, M. Bessaud, M. Grandadam, S. Murri, H. J. Tolou, and C. N. Peyrefitte, “Development of a tagman® RT-PCR assay without RNA extraction step for the detection and quantification of African chikungunya viruses,” *Journal of Virological Methods*, vol. 124, no. 1-2, pp. 65–71, 2005.

[103] M. de Oña, and S. Melón, “Simultaneous detection of dengue viruses,” *Journal of Virological Methods*, vol. 80, pp. 53–55, 2001.

[104] J. G. Peter, L. S. Zijenah, D. Chanda et al., “Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-positive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomised controlled trial,” *The Lancet*, vol. 387, no. 10024, pp. 1187–1197, 2016.
tuberculosis,” *Emerging Microbes & Infections*, vol. 8, no. 1, pp. 1361–1369, 2019.

[98] G. Xiao, X. He, S. Zhang et al., “Cas12a/guide RNA-based platform for rapid and accurate identification of major *Mycobacterium* species,” *Journal of Clinical Microbiology*, vol. 58, no. 2, Article ID e01368-19, 2020.

[99] C. Lyu, H. Shi, Y. Cui et al., “CRISPR-based biosensing is prospective for rapid and sensitive diagnosis of pediatric tuberculosis,” *International Journal of Infectious Diseases*, vol. 101, pp. 183–187, 2020.

[100] Y. Zhang, L. Qian, W. Wei et al., “Paired design of dCas9 as a systematic platform for the detection of featured nucleic Acid sequences in pathogenic strains,” *ACS Synthetic Biology*, vol. 6, no. 2, pp. 211–216, 2017.

[101] A. R. Fooks, F. Cliquet, S. Finke et al., “Rabies,” *Nature Reviews Disease Primers*, vol. 3, Article ID 17091, 2017.

[102] K. Hampson, L. Coudeville, T. Lembo et al., “Estimating the global burden of endemic canine Rabies,” *PLoS Neglected Tropical Diseases*, vol. 9, no. 4, Article ID e0003709, 2015.

[103] A. C. Jackson, “Rabies pathogenesis,” *Journal of Neuro-Virology*, vol. 8, no. 4, pp. 267–269, 2002.

[104] M. Mallewa, A. R. Fooks, D. Banda et al., “Rabies encephalitis in malaria-endemic area, Malawi, Africa,” *Emerging Infectious Diseases*, vol. 13, no. 1, pp. 136–139, 2007.

[105] R. P. Aravindhubabu, S. Manoharan, and P. Ramadass, “Diagnostic evaluation of RT-PCR-ELISA for the detection of rabies virus,” *Virusdisease*, vol. 25, no. 1, pp. 120–124, 2014.

[106] S. Dürr, S. Naïssengar, R. Mindekem et al., “Rabies diagnosis for developing countries,” *PLoS Neglected Tropical Diseases*, vol. 2, no. 3, Article ID e206, 2008.

[107] K. N. Prabhu, S. Isloor, B. H. Veeresh et al., “Application and comparative evaluation of fluorescent antibody, immuno-histochemistry and reverse transcription polymerase chain reaction tests for the detection of rabies virus antigen or nucleic acid in brain samples of animals suspected of rabies in India,” *Veterinary Sciences*, vol. 5, no. 1, p. 24, 2018.

[108] R. S. Mani, S. N. Madhusudana, A. Mahadevan, V. Reddy, A. Y. Belludi, and S. K. Shankar, “Utility of real-time taqman PCR for antemortem and postmortem diagnosis of human rabies,” *Journal of Medical Virology*, vol. 86, no. 10, pp. 1804–1812, 2014.

[109] L. Dacheux, F. Larrous, R. Lavenir et al., “Dual combined real-time reverse transcription polymerase chain reaction assay for the diagnosis of lyssavirus infection,” *PLoS Neglected Tropical Diseases*, vol. 10, no. 7, Article ID e0004812, 2016.

[110] M. Faye, L. Dacheux, M. Weidmann et al., “Development and validation of sensitive real-time RT-PCR assay for broad detection of rabies virus,” *Journal of Virological Methods*, vol. 243, pp. 120–130, 2017.

[111] M. Ren, H. Mei, J. Zhou, M. Zhou, H. Han, and L. Zhao, “Early diagnosis of rabies virus infection by RPA-CRISPR techniques in a rat model,” *Archives of Virology*, vol. 166, no. 4, pp. 1083–1092, 2021.